Exelixis (EXEL) Total Current Liabilities (2010 - 2026)
Exelixis (EXEL) recorded quarterly Total Current Liabilities of $371.0 million in Q2 2026, down 8.55% quarter-over-quarter from $405.6 million in Q1 2026, and down 7.05% on a YoY basis from $399.1 million in Q2 2025.
Exelixis (EXEL) Total Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $371.0 million for Q2 2026.
- In Q2 2026, Total Current Liabilities fell 7.05% year-over-year to $371.0 million; the TTM figure through Apr 2026 stood at $371.0 million (down 7.05% YoY), while the FY2026 annual figure was $405.6 million, changed 0.46% from the prior year.
- Total Current Liabilities was $371.0 million for Q2 2026 at Exelixis, down from $405.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $405.6 million in Q1 2026 to a low of $289.1 million in Q2 2022.
- Historically, Total Current Liabilities has averaged $356.5 million across 5 years, with a median of $371.0 million in 2026.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities surged 35.5% in 2022, then dropped 7.05% in 2026.
- A 5-year view of Total Current Liabilities shows it stood at $324.4 million in 2022, then advanced by 21.56% to $394.3 million in 2023, then climbed by 0.02% to $394.3 million in 2024, then declined by 5.22% to $373.8 million in 2025, then fell by 0.75% to $371.0 million in 2026.
- The last three Total Current Liabilities figures came in at $371.0 million (Q2 2026), $405.6 million (Q1 2026), and $373.8 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 72.86 Mn |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 370.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 370.98 Mn |
| Jan 2, 2026 | 405.64 Mn |
| Oct 3, 2025 | 373.78 Mn |
| Jul 4, 2025 | 336.11 Mn |
| Apr 4, 2025 | 399.10 Mn |
| Jan 3, 2025 | 403.77 Mn |
| Sep 27, 2024 | 394.35 Mn |
| Jun 28, 2024 | 345.70 Mn |
| Mar 29, 2024 | 373.01 Mn |
| Dec 29, 2023 | 394.28 Mn |
| Sep 29, 2023 | 376.82 Mn |
| Jun 30, 2023 | 339.62 Mn |
| Mar 31, 2023 | 327.60 Mn |
| Dec 30, 2022 | 324.36 Mn |
| Sep 30, 2022 | 301.73 Mn |
| Jul 1, 2022 | 304.52 Mn |
| Apr 1, 2022 | 289.08 Mn |
| Dec 31, 2021 | 337.59 Mn |
| Oct 1, 2021 | 269.51 Mn |
| Jul 2, 2021 | 255.33 Mn |